{"id":"W2967622554","doi":"10.1111/ene.14056","title":"Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study","year":2019,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Japan Society for the Promotion of Science; Pfizer Japan; Grifols; Mitsubishi Tanabe Pharma Corporation; Bayer Yakuhin; Teijin Pharma; Prinses Beatrix Spierfonds; Ono Pharmaceutical; Eisai; Ministry of Education, Culture, Sports, Science and Technology; Shionogi; Argenx; Union Chimique Belge; Kissei; Boehringer Ingelheim Japan; Ministry of Health, Labour and Welfare; Japan Blood Products Organization; Bristol-Myers Squibb; CSL Behring; Kowa Company; European Commission; Pfizer","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; EQ-5D; Randomized controlled trial; Health related quality of life; Antibody; Immunology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007796054,0.0002543765,0.0005118772,0.0001797355,0.00007098429,0.00002502635,0.0002753547,0.00002927052,0.00005683473],"category_scores_gemma":[0.0002037036,0.0001487434,0.0001336326,0.0002474327,0.00009870415,0.00009500861,0.0001243632,0.001084876,0.00003245519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004365436,"about_ca_system_score_gemma":0.000208122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000125239,"about_ca_topic_score_gemma":0.00002710084,"domain_scores_codex":[0.9966282,0.001281101,0.0009907095,0.0002841505,0.0004122726,0.0004035655],"domain_scores_gemma":[0.9983586,0.00018674,0.0007515262,0.000449856,0.0001509812,0.000102274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003053432,0.0003878399,0.92693,0.00002328651,0.0001065119,0.05664675,0.001755453,0.001479016,0.003891687,0.000006175168,0.00005606182,0.005663759],"study_design_scores_gemma":[0.005664873,0.0257591,0.9533273,0.0000492678,0.00008312666,0.01014133,0.0008614848,0.0001783511,0.00001252784,0.000004855969,0.003755251,0.0001625413],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965305,0.0003692845,0.000007979984,0.001123445,0.0004626229,0.0005362467,7.100001e-7,0.00002682547,0.0009423415],"genre_scores_gemma":[0.9971077,0.00005625287,0.00001768826,0.002584002,0.00009568216,0.000001725142,6.114532e-7,0.00007024212,0.00006610533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04650542,"threshold_uncertainty_score":0.6065581,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007972421909463312,"score_gpt":0.2277911404920299,"score_spread":0.2198187185825665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}